{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T02:07:58Z","timestamp":1778724478452,"version":"3.51.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Min Sun"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Imaging"],"DOI":"10.1186\/s12880-026-02304-4","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T09:27:32Z","timestamp":1774949252000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Value of intratumoral and peritumoral radiomics based on DCE-MRI in predicting HER2-low and HER2-zero in breast cancer"],"prefix":"10.1186","volume":"26","author":[{"given":"Min","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruoming","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weining","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiqing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lixia","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duo","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuai","family":"Quan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuojun","family":"Geng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"issue":"15","key":"2304_CR1","first-page":"2568","volume":"130","author":"MB Nierengarten","year":"2024","unstructured":"Nierengarten MB. Global cancer statistics 2022: The report offers a view on disparities in the incidence and mortality of cancer by sex and region worldwide and on the areas needing attention [J]. Cancer-am cancer soc. 2024;130(15):2568.","journal-title":"Cancer-am cancer soc"},{"issue":"4","key":"2304_CR2","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/modpathol.2013.38","volume":"26","author":"HJ Lee","year":"2013","unstructured":"Lee HJ, Park SY. Reply to \u2018Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance\u2019. Mod PATHOL. 2013;26(4):610\u20131.","journal-title":"Mod PATHOL"},{"issue":"20","key":"2304_CR3","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH, et al. Human Epidermal Growth Factor Receptor 2 Testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update [J]. J clin oncol. 2018;36(20):2105\u201322.","journal-title":"J clin oncol"},{"issue":"4","key":"2304_CR4","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S1470-2045(17)30021-9","volume":"18","author":"A Llombart-Cussac","year":"2017","unstructured":"Llombart-Cussac A, Cort\u00e9s J, Par\u00e9 L, et al. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial [J]. Lancet oncol. 2017;18(4):545\u201354.","journal-title":"Lancet oncol"},{"issue":"1","key":"2304_CR5","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s12957-024-03530-2","volume":"22","author":"S Yan","year":"2024","unstructured":"Yan S, Zhao W, Dong Y, et al. Unveiling the mysteries of HER2-low expression in breast cancer: pathological response, prognosis, and expression level alterations [J]. World J Surg Oncol. 2024;22(1):248.","journal-title":"World J Surg Oncol"},{"issue":"1","key":"2304_CR6","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12916-022-02346-9","volume":"20","author":"G Zhang","year":"2022","unstructured":"Zhang G, Ren C, Li C, et al. Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status [J]. BMC Med. 2022;20(1):142.","journal-title":"BMC Med"},{"issue":"1","key":"2304_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41523-020-00208-2","volume":"7","author":"F Schettini","year":"2021","unstructured":"Schettini F, Chic N, Bras\u00f3-Maristany F, et al. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer [J]. NPJ breast cancer. 2021;7(1):1.","journal-title":"NPJ breast cancer"},{"key":"2304_CR8","doi-asserted-by":"crossref","unstructured":"Eiger D, Agostinetto E, Sa\u00fade-Conde R, et al. The exciting new field of HER2-Low breast cancer treatment. Cancers (Basel). 2021;13(5).","DOI":"10.3390\/cancers13051015"},{"issue":"1","key":"2304_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced breast cancer [J]. New engl j med. 2022;387(1):9\u201320.","journal-title":"New engl j med"},{"issue":"12","key":"2304_CR10","doi-asserted-by":"publisher","first-page":"101330","DOI":"10.1016\/j.xcrm.2023.101330","volume":"4","author":"H Kameyama","year":"2023","unstructured":"Kameyama H, Dondapati P, Simmons R, et al. Needle biopsy accelerates pro-metastatic changes and systemic dissemination in breast cancer: Implications for mortality by surgery delay [J]. Cell Rep Med. 2023;4(12):101330.","journal-title":"Cell Rep Med"},{"issue":"7","key":"2304_CR11","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/s43018-021-00229-1","volume":"2","author":"N Pasha","year":"2021","unstructured":"Pasha N, Turner NC. Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment [J]. Nat Cancer. 2021;2(7):680\u201392.","journal-title":"Nat Cancer"},{"key":"2304_CR12","doi-asserted-by":"crossref","unstructured":"Vishwa P. Michael, Radiomics: a new application from established techniques [J]. Expert Rev Precision Med Drug Dev. 2016;1(2).","DOI":"10.1080\/23808993.2016.1164013"},{"issue":"1","key":"2304_CR13","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/med.21846","volume":"42","author":"J Guiot","year":"2021","unstructured":"Guiot J, Vaidyanathan A, Deprez L, et al. A review in radiomics: Making personalized medicine a reality via routine imaging. MED RES REV. 2021;42(1):426\u201340.","journal-title":"MED RES REV"},{"issue":"10087","key":"2304_CR14","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1016\/S0140-6736(16)32417-5","volume":"389","author":"S Loibl","year":"2017","unstructured":"Loibl S, Gianni L. HER2-positive breast cancer [J]. Lancet. 2017;389(10087):2415\u201329.","journal-title":"Lancet"},{"issue":"2","key":"2304_CR15","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1703643","volume":"377","author":"G Von Minckwitz","year":"2017","unstructured":"Von Minckwitz G, Procter M, DE Azambuja E, et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive breast cancer [J]. New engl j med. 2017;377(2):122\u201331.","journal-title":"New engl j med"},{"issue":"2","key":"2304_CR16","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","volume":"22","author":"SM Swain","year":"2023","unstructured":"Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: advances and future directions [J]. Nat rev drug discov. 2023;22(2):101\u201326.","journal-title":"Nat rev drug discov"},{"issue":"10075","key":"2304_CR17","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","volume":"389","author":"D Cameron","year":"2017","unstructured":"Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years\u2019 follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial [J]. Lancet. 2017;389(10075):1195\u2013205.","journal-title":"Lancet"},{"issue":"5","key":"2304_CR18","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1200\/JCO.19.01455","volume":"38","author":"L Fehrenbacher","year":"2020","unstructured":"Fehrenbacher L, Cecchini RS, Geyer CE, et al. NSABP B-47\/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive breast cancer Negative for HER2 by FISH and With IHC 1\u2009+\u2009or 2 [J]. J clin oncol. 2020;38(5):444\u201353.","journal-title":"J clin oncol"},{"issue":"3","key":"2304_CR19","doi-asserted-by":"publisher","first-page":"e243345","DOI":"10.1001\/jamanetworkopen.2024.3345","volume":"7","author":"T Khoury","year":"2024","unstructured":"Khoury T, Mendicino L, Payne Ondracek R, et al. Clinical, Epidemiologic, and Pathologic Significance of ERBB2-Low Expression in breast cancer [J]. JAMA Netw Open. 2024;7(3):e243345.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"2304_CR20","first-page":"188849","volume":"1878","author":"P Fan","year":"2023","unstructured":"Fan P, Xu K. Antibody-drug conjugates in breast cancer: Marching from HER2-overexpression into HER2-low [J]. Bba-rev cancer. 2023;1878(1):188849.","journal-title":"Bba-rev cancer"},{"issue":"17","key":"2304_CR21","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1200\/JCO.19.02318","volume":"38","author":"S Modi","year":"2020","unstructured":"Modi S, Park H, Murthy RK, et al. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced breast cancer: Results From a Phase Ib Study [J]. J clin oncol. 2020;38(17):1887\u201396.","journal-title":"J clin oncol"},{"issue":"5","key":"2304_CR22","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1007\/s12282-024-01600-7","volume":"31","author":"T Yamashita","year":"2024","unstructured":"Yamashita T, Sohn JH, Tokunaga E, et al. Trastuzumab deruxtecan versus treatment of physician\u2019s choice in previously treated Asian patients with HER2-low unresectable\/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study. BREAST CANCER-TOKYO. 2024;31(5):858\u201368.","journal-title":"BREAST CANCER-TOKYO"},{"issue":"8","key":"2304_CR23","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.annonc.2023.05.008","volume":"34","author":"P Tarantino","year":"2023","unstructured":"Tarantino P, Viale G, Press MF, et al. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer [J]. Ann oncol. 2023;34(8):645\u201359.","journal-title":"Ann oncol"},{"issue":"5","key":"2304_CR24","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1097\/RCT.0000000000001474","volume":"47","author":"WY Yue","year":"2023","unstructured":"Yue WY, Zhang HT, Gao S, et al. Predicting Breast Cancer Subtypes Using Magnetic Resonance Imaging Based Radiomics With Automatic Segmentation. J COMPUT ASSIST TOMO. 2023;47(5):729\u201337.","journal-title":"J COMPUT ASSIST TOMO"},{"issue":"7","key":"2304_CR25","doi-asserted-by":"publisher","first-page":"e28722","DOI":"10.1016\/j.heliyon.2024.e28722","volume":"10","author":"J Zhou","year":"2024","unstructured":"Zhou J, Yu X, Wu Q, et al. Radiomics analysis of intratumoral and different peritumoral regions from multiparametric MRI for evaluating HER2 status of breast cancer: A comparative study [J]. Heliyon. 2024;10(7):e28722.","journal-title":"Heliyon"},{"key":"2304_CR26","doi-asserted-by":"publisher","first-page":"1385352","DOI":"10.3389\/fonc.2024.1385352","volume":"14","author":"L Yin","year":"2024","unstructured":"Yin L, Zhang Y, Wei X, et al. Preliminary study on DCE-MRI radiomics analysis for differentiation of HER2-low and HER2-zero breast cancer. Front Oncol. 2024;14:1385352.","journal-title":"Front Oncol"},{"issue":"2","key":"2304_CR27","doi-asserted-by":"publisher","first-page":"e222646","DOI":"10.1148\/radiol.222646","volume":"308","author":"T Ramtohul","year":"2023","unstructured":"Ramtohul T, Djerroudi L, Lissavalid E, et al. Multiparametric MRI and Radiomics for the Prediction of HER2-Zero, -Low, and -Positive breast cancers [J]. Radiology. 2023;308(2):e222646.","journal-title":"Radiology"},{"issue":"9","key":"2304_CR28","doi-asserted-by":"publisher","first-page":"6132","DOI":"10.1007\/s00330-024-10641-7","volume":"34","author":"S Zheng","year":"2024","unstructured":"Zheng S, Yang Z, Du G, et al. Discrimination between HER2-overexpressing, -low-expressing, and -zero-expressing statuses in breast cancer using multiparametric MRI-based radiomics [J]. Eur radiol. 2024;34(9):6132\u201344.","journal-title":"Eur radiol"},{"issue":"4","key":"2304_CR29","doi-asserted-by":"publisher","first-page":"e2330603","DOI":"10.2214\/AJR.23.30603","volume":"222","author":"Y Peng","year":"2024","unstructured":"Peng Y, Zhang X, Qiu Y, et al. Development and Validation of MRI Radiomics Models to Differentiate HER2-Zero, -Low, and -Positive breast cancer [J]. Am j roentgenol. 2024;222(4):e2330603.","journal-title":"Am j roentgenol"},{"issue":"3","key":"2304_CR30","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.bbamcr.2015.05.036","volume":"1863","author":"GL S","year":"2016","unstructured":"GL S. The hypoxic tumor microenvironment: A driving force for breast cancer progression [J]. Biochim Biophys Acta. 2016;1863(3):382\u201391.","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"2304_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-017-4153-4","volume":"163","author":"KT Hwang","year":"2017","unstructured":"Hwang KT, Kim YA, Kim J, et al. The influences of peritumoral lymphatic invasion and vascular invasion on the survival and recurrence according to the molecular subtypes of breast cancer [J]. breast cancer Res Treat. 2017;163(1):1\u201312.","journal-title":"breast cancer Res Treat"},{"key":"2304_CR32","doi-asserted-by":"crossref","unstructured":"Uematsu T. Focal breast edema associated with malignancy on T2-weighted images of breast MRI: peritumoral edema, prepectoral edema, and subcutaneous edema [J]. Breast Cancer-Tokyo. 2015;22(1):66\u201370.","DOI":"10.1007\/s12282-014-0572-9"},{"key":"2304_CR33","doi-asserted-by":"crossref","unstructured":"Li C, Song L, Yin J. Intratumoral and peritumoral radiomics based on functional parametric maps from breast DCE-MRI for prediction of HER-2 and Ki-67 status [J]. J Magn Reson Imaging. 2021;54(3).","DOI":"10.1002\/jmri.27651"},{"issue":"Suppl 1","key":"2304_CR34","first-page":"S223","volume":"29","author":"J Ding","year":"2020","unstructured":"Ding J, Chen S, Serrano Sosa M, et al. Optimizing the Peritumoral Region Size in Radiomics Analysis for Sentinel Lymph Node Status Prediction in Breast Cancer. ACAD RADIOL. 2020;29(Suppl 1):S223\u20138.","journal-title":"ACAD RADIOL"},{"issue":"Suppl 10","key":"2304_CR35","first-page":"521","volume":"19","author":"NM Braman","year":"2017","unstructured":"Braman NM, Etesami M, Prasanna P, et al. Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI [J]. breast cancer Research: BCR. 2017;19(Suppl 10):521\u201330.","journal-title":"breast cancer Research: BCR"},{"issue":"4","key":"2304_CR36","doi-asserted-by":"publisher","first-page":"e192561","DOI":"10.1001\/jamanetworkopen.2019.2561","volume":"2","author":"N Braman","year":"2019","unstructured":"Braman N, Prasanna P, Whitney J, et al. Association of Peritumoral Radiomics With Tumor Biology and Pathologic Response to Preoperative Targeted Therapy for HER2 (ERBB2)-Positive Breast Cancer. JAMA Netw Open. 2019;2(4):e192561.","journal-title":"JAMA Netw Open"}],"container-title":["BMC Medical Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12880-026-02304-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-026-02304-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-026-02304-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T01:15:19Z","timestamp":1778721319000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12880-026-02304-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2304"],"URL":"https:\/\/doi.org\/10.1186\/s12880-026-02304-4","relation":{},"ISSN":["1471-2342"],"issn-type":[{"value":"1471-2342","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"8 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our study complied with the Declaration of Helsinki. This study was a retrospective study and was approved by the Cangzhou Central Hospital Medical Ethics Committee and exempted from informed consent (approval number: 2023-279-01).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"252"}}